This is a 24-week randomized, double-blind, placebo-controlled trial. We will enroll patients
with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10
sessions in total) during the first 2 weeks of the study, and will also be allocated randomly
to either of 2 treatment groups for 24 weeks: (1) DAOIB group; (2) placebo group. We will
assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We
hypothesize that augmentation with DAOIB will yield better effect than tDCS alone in
improving the cognitive function, global functioning and quality of life in patients with
aMCI or mild AD.